This paper evaluates the natural history of prostate cancer in heterogeneous cohort of men treated with HT.
Yossepowitch
Ofer
O
Department of Surgery - Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. yossepoo@mskcc.org
D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D049451:Nomograms; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate
D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen